Table 3.
Factors associated with subjective symptoms in patients receiving antiretroviral therapy, Mombasa, Kenya*
| Predictor variable | Subjective symptoms | Univariate analysis | ||
|---|---|---|---|---|
| Present, n = 69(68%) | Absent, n = 33(32%) | Odds ratio (95% confidence interval) | P | |
| Median (quartile) years of age | 41 (34–48) | 38 (32–44) | 1.0 (1.0–1.1) | 0.12 |
| Median (quartile) months receiving ART | 10.3 (5.1–16.4) | 9.8 (4.4–15.4) | 1.0 (1.0–1.1) | 0.72 |
| Female | 45 (65%) | 19 (58%) | 0.7 (0.3–1.7) | 0.46 |
| Median (quartile) baseline kilograms of weight | 56 (50–63) | 58 (52–62) | 1.0 (0.9–1.0) | 0.57 |
| Median (quartile) baseline centimeters of height | 161.5 (155–169) | 168.5 (160.5–172) | 1.0 (0.92–1.01) | 0.12 |
| Median (quartile) baseline CD4 cell count | 144 (58–199) | 140 (99–179) | 1.0 (0.99–1.0) | 0.41 |
| CD4 cell count < 100 cells/mm3 | 26 (38%) | 9 (27%) | 1.6 (0.7–4.0) | 0.30 |
| Clinical diagnosis of AIDS | 44 (64%) | 19 (58%) | 1.3 (0.6–3.0) | 0.55 |
| Any D4T use | 64 (93%) | 32 (97%) | 0.4 (0.04–3.6) | 0.41 |
| Current D4T use | 58 (84%) | 30 (91%) | 0.5 (0.1–2.0) | 0.35 |
| Past D4T use | 6 (9%) | 2 (6%) | 1.5 (0.3–7.7) | 0.65 |
| Current or past INH use | 12 (17%) | 6 (18%) | 0.9 (0.3–2.8) | 0.92 |
*
Values are no. (%) unless otherwise indicated. ART = antiretroviral therapy; AIDS = acquired immunodeficiency syndrome; D4T = stavudine; INH = iosniazid.